| Study |
Trimester |
Inclusion criteria |
Controls selection |
Quality score |
Regimen |
Infected |
Not infected |
Lost to follow‐up |
% Infected children |
| Desmonts 1984 |
all |
seroconversion ; "significant increase in IgG"; "clinical signs and high levels of IgG" |
unknown; historical controls (seroconversions prior to screening) |
3 |
spiramycin (2‐3 g/d) for at least one month : 388 |
88 |
297 |
3 |
22 (95% CI 18, 27) |
| |
|
|
|
|
no treatment : 154 |
85 |
60 |
9 |
52 (95% CI 44, 60) |
| Douche 1996 |
all |
seroconversion |
late seroconversions
inadequate follow‐up |
4 |
spiramycin (2g/d) : 64 |
9 |
60 |
0 |
13 (95% CI 6, 24) |
| |
|
|
|
|
spiramycin + PS after positive antenatal diagnosis : 5 |
|
|
|
|
| |
|
|
|
|
no treatment : 29 |
29 |
0 |
0 |
100 (95% CI 63, 100) |
| Excler 1985 |
first |
seroconversion or increase in IgG |
unknown |
2 |
spiramycin (3g/d) : 31 |
2 |
29 |
0 |
6 (95% CI 1, 23) |
| |
|
|
|
|
no treatment : 4 |
0 |
4 |
0 |
0 (95% CI 0, 60) |
| |
second |
|
|
|
spiramycin : 55 |
15 |
40 |
0 |
27 (95% CI 16, 41) |
| |
|
|
|
|
no treatment : 13 |
5 |
8 |
0 |
38 (95% CI 15, 68) |
| |
third |
|
|
|
spiramycin: 18 |
|
|
|
|
| |
|
|
|
|
no treatment : 13 |
26 |
99 |
0 |
21 (95% CI 14, 29) |
| |
all |
|
|
|
spiramycin : 104 |
22 |
82 |
0 |
21 (95% CI 14, 30) |
| |
|
|
|
|
no treatment : 30 |
26 |
99 |
0 |
21 (95% CI 14, 29) |
| Knerer 1995 |
14‐29 week |
seroconversion |
untreated patients or non‐compliers |
4 |
spiramycin (3 g/d) : 9 |
0 |
9 |
0 |
0 (95% CI 0, 37) |
| |
|
|
|
|
no treatment : 2 |
2 |
0 |
0 |
100 (95% CI 20, 100) |
| Kraubig 1966 |
all |
seroconversion (18) ; increase (x2) dye test ; dye test > 1000 |
unknown |
4 |
P + Su : 59 |
3 |
56 |
0 |
5 (95% CI 1, 15) |
| |
|
|
|
|
no treatment : 84 |
14 |
70 |
0 |
17 (95% CI 10, 27) |
| Lambotte 1976 |
all |
seroconversion |
untreated patients or non‐compliers |
4 |
spiramycin + S (3g/d each, 4 weeks/6) : 28 |
0 |
28 |
0 |
0 (95% CI 0, 15) |
| |
|
|
|
|
no treatment : 101 |
10 |
91 |
0 |
10 (95% CI 5, 18) |
| Roux 1976 |
all |
seroconversion (10) ; evolutive infection* (18) ; high IgG levels (25) |
late seroconversions (5)
inadequate follow‐up (1) |
3 |
spiramycin (3 g/d) : 47 |
2 |
43 |
2 |
4 (95% CI 0.7‐15) |
| |
|
|
|
|
no treatment : 6 |
5 |
1 |
0 |
83 (95% CI 36, 99) |
| Thoumsin 1992 |
all |
seroconversion |
unknown |
2 |
spiramycin + PS (dose unknown) : 99 |
10 |
89 |
0 |
10 (95% CI 5‐, 8) |
| |
|
|
|
|
no treatment : 101 |
10 |
91 |
0 |
10 (95% CI 5, 20) |
| Wallon 1997 |
all |
seroconversion |
Lyon : ‐
Copenhagen : screening at delivery |
4 |
spiramycin (3 g/d) ± PS : 564 |
141 |
381 |
42 |
24 (95% CI 20, 27) |
| |
|
|
|
|
no treatment : 125 |
26 |
99 |
0 |
21 (95% CI 14, 29) |
| Foulon 1999 |
all |
seroconversion |
unknown |
2 |
spiramycin ± PS or Az: 119 |
46 |
69 |
4 |
39 (95% CI 30‐48) |
| |
|
|
|
|
no treatment: 25 |
18 |
7 |
0 |
72 (95% CI 50‐87) |
